Dysplastic nevus syndrome and pancreatic cancer: A case report

LILIANA GABRIELA POPA1,2, CALIN GIURCANEANU1,2, CORNELIA NITIPIR3,4, ANA MARIA POPA3, CRISTIANA STOICA1, CRISTINA BEIU2, TIBERIU TEBEICA5, SILVIUS NEGOITA6,7 and MARA MADALINA MIHAI1,2

1Department of Dermatology, ‘Elias’ Emergency University Hospital, 011461 Bucharest; 2Department of Oncologic Dermatology, ‘Elias’ Emergency University Hospital, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest; 3Department of Oncology, ‘Elias’ Emergency University Hospital, 011461 Bucharest; 4Department of Oncology, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest; 5Department of Dermatopathology, ‘Dr. Leventer’ Centre, 011216 Bucharest; 6Department of Anaesthesiology and Intensive Care, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest; 7Department of Anaesthesiology and Intensive Care, ‘Elias’ Emergency University Hospital, 011461 Bucharest, Romania

Received May 31, 2021; Accepted June 30, 2021

DOI: 10.3892/etm.2021.10953

Abstract. Multiple primary cancers may occur in the same patient, with a prevalence that follows an ascendant trend. Their development is dictated by a complex interplay between a variety of factors, both patient-dependent and external. The case of a 38-year-old female patient diagnosed and treated for pancreatic cancer (PC) is presented in whom the digital dermoscopic monitoring of melanocytic nevi revealed a marked change of two nevi that acquired rapidly highly atypical features. They were surgically excised and the histopathological examination revealed two completely excised dysplastic compound nevi. Clinicians should be aware of the strong association between dysplastic nevus syndrome and PC, a malignancy associated with an extremely poor prognosis. Familial atypical multiple mole melanoma syndrome (FAMMM) predisposes to the development of melanoma, pancreatic cancer and other neoplasms. The common genetic background of PC and hereditary melanoma is discussed and the importance of regular skin checkup and screening for PC in these patients is underlined.

Introduction

Due to the tremendous efforts of researchers and clinicians during the past few decades, in numerous parts of the world early diagnosis of cancer is readily achievable. Survival from cancer has considerably increased as a result of systematic screening and the development of novel cancer treatments with improved efficacy. Thus, given the growing number of cancer survivors, the opportunity arose to study the genetic background of these patients, environmental exposure to carcinogens, the long-term side effects of cancer treatments and their risk of developing subsequent primary cancers.

According to the studies carried out, to date, multiple primary cancers occur with a frequency ranging from 2 to 17% (1). As anticipated, their prevalence follows an ascendant trend (2). The development of multiple cancers is dictated by a complicated interplay between a variety of factors, both patient-dependent (genetic predisposition, immune deficiencies, hormonal dysfunctions) and external (infections, exposure to ultraviolet radiation, ionizing radiation, smoking, alcohol consumption, dietary factors). Chemotherapy and/or radiotherapy for previous cancers greatly increase the risk for the development of subsequent neoplasia, either hematologic malignancies or solid tumors (3,4).

Despite the notable progress in oncologic treatment, pancreatic cancer (PC) still portends an extremely poor prognosis, with a five-year survival rate after radical surgery of 10% for node-positive disease, which is the case in approximately two thirds of patients and 30% for node-negative disease (5,6). This is one of the reasons the appearance of a second or multiple cancers in PC patients was long considered highly improbable (7). However, a search of the literature reveals several reports of single or multiple extra-pancreatic cancers, located in the digestive tract, lung, breast, prostate, kidney, and skin arising in patients previously or consequently diagnosed with PC (7).

Although a series of studies (8,9) concluded that the risk of PC is increased in families with atypical multiple mole melanoma syndrome (FAMMM), also named dysplastic nevus syndrome, other studies have not confirmed this hypothesis (7,10). The controversy and puzzle regarding a potential association between PC and melanoma in some patients

Correspondence to: Dr Cristiana Stoica, Department of Dermatology, ‘Elias’ Emergency University Hospital, 17 Marasti Boulevard, 011461 Bucharest, Romania
E-mail: dobrescucristiana@yahoo.ro

Key words: melanoma, pancreatic cancer, cyclin-dependent kinase inhibitor 2A, multiple primary neoplasms, dysplastic nevus syndrome, familial atypical multiple mole-melanoma
have been recently untangled owing to in-depth genetic studies (11-15). The case of a young patient diagnosed and treated for PC is presented, in whom digital dermoscopic follow-up of melanocytic nevi proved to be lifesaving, as it revealed the rapid change of two nevi that acquired highly atypical features. The common genetic background of PC and hereditary melanoma and the optimal approach for these patients is also discussed.

**Case report**

A 38-year-old female patient was referred to the Department of Dermatology, ‘Elias’ Emergency University Hospital, in November 2019, for the clinical and dermoscopic assessment of multiple pigmented nevi. The patient had been recently diagnosed with PC with duodenal invasion and had undergone pancreaticoduodenectomy, followed by the initiation of systemic chemotherapy with 5-fluorouracil, irinotecan, oxaliplatin and folinic acid (the FOLFIRINOX regimen). The study was approved by the Ethics Committee of Elias Emergency University Hospital, Bucharest, Romania (approval no. 4902). Written informed consent was provided by the patient.

The patient had a positive family history for oncologic diseases on the paternal side. Three paternal aunts had been diagnosed with solid neoplasms: One had succumbed shortly after being diagnosed with a digestive cancer (the patient was not aware of the exact location of the neoplasm), another had been diagnosed with breast cancer at a young age and the third with thyroid cancer.

The physical examination was within normal limits, except for the presence of numerous atypical melanocytic nevi located on the trunk and limbs.

Close digital dermoscopic monitoring of the atypical nevi, at three-month intervals was initially performed. Contrary to the advice of the dermatologist, the patient missed several scheduled control visits and only appeared a year later, when significant changes in size, shape and structure could be observed on digital dermoscopic examination in two melanocytic nevi, located in the umbilical region and on the inferior abdominal integument, respectively.

The melanocytic lesion located in the periumbilical region was a reticular-homogenous nevus with a diameter of ~7.5 mm. It presented marked asymmetry, irregular borders, atypical pigment network, uneven pigmentation with multiple areas of hyperpigmentation and structureless, hypopigmented areas, irregularly distributed brown and black globules and dots, as well as pseudopods (Fig. 1). Compared with the previous examination, the nevus had increased in size, had changed its shape and exhibited intensification of pigmentation. It had also gained the striking atypical features aforementioned.

The second changing nevus was a compound nevus, approximately 1 cm in diameter, located in the inferior abdominal area. It exhibited asymmetry, was ill-defined, had irregular borders and pigment variegation. The junctional component displayed an atypical pigment network, with focal hyperpigmentation, and irregularly distributed brown and black globules and dots (Fig. 2). Similar to the previously described nevus, it had increased in size and had slightly changed its shape. The described nevi were surgically excised with a 0.5 cm safety margin.

The histopathologic examination was performed with the following parameters: The nevi were fixed with 10% neutral buffered formalin at 21°C for 24 h on histopathological sections of a 4-µm thickness. Subsequently, staining was performed with hematoxylin at 21°C for 2 min and eosin at 21°C for 30 sec. A light microscope (Olympus BX43; Olympus Corporation) was used for observation. The histopathological examination revealed two completely excised dysplastic compound nevi (Figs. 3 and 4).

The melanocytic nevi of the patient were carefully monitored thereafter, but no further changes have been noted.

**Discussion**

According to the numerous studies carried out thus far, an increased risk of melanoma was observed in patients diagnosed with non-melanoma skin cancers, hematologic malignancies, nervous system neoplasms, testicular and breast cancer (11). Common genetic abnormalities, immunological dysfunctions or exposure to environmental risk factors may all play a role.

Conversely, in melanoma patients, a series of second primary cancers appear to develop with a higher frequency than anticipated. Among these are non-melanoma skin cancers, nervous system cancer, chronic lymphocytic leukemia, breast, renal, thyroid, oropharyngeal, testicular, digestive tract, connective tissue, and lung cancers (11).

Additional primary cancers have also been detected in the setting of FAMMM, also known as dysplastic nevus syndrome (8,12,16), an autosomal dominant disease with incomplete penetrance and high phenotypic heterogeneity (17). Kindreds with FAMMM are not only predisposed to develop melanoma, but also certain extracutaneous cancers, particularly pancreatic, breast, lung, and lymphoreticular system cancer (8,16,17).

Genetic susceptibility is decisive for the appearance of hereditary and sporadic melanomas. The most important melanoma susceptibility gene is cyclin-dependent kinase inhibitor 2A (CDKN2A/p16), harbored on chromosome 9p21. Mutations of this gene have been detected in 20-60% of families predisposed to hereditary melanoma (13-15,18). Mutations in CDKN2A/ARF and other genes, encoding for cyclin-dependent kinase 4 (CDK4; located on chromosome 12q14.1), telomerase reverse transcriptase (TERT; located on chromosome 3p15.33), melanocyte inducing transcription factor (MITF; located on chromosome 3p13), ubiquitin carboxyl-terminal hydrolase (BAP1; located on chromosome 3p21.1), protection of telomeres 1 (POT1; located on chromosome 7q31.33) are less frequently encountered (18).

CDKN2A was also revealed to be implicated in pancreatic tumorigenesis (10,19,20), thus explaining the propensity for PC in FAMMM families.

CDKN2A codes for p16 INK4 and p14 alternative reading frame (ARF). p16 INK4 inhibits the activity of cyclin D1-CDK4 complex, which phosphorylates the retinoblastoma protein in order to allow progression to the G1 phase of the cell cycle (21). Therefore, CDKN2A/p16 impedes cell growth and acts as a tumor suppressor gene. In Northern Europe, one of the most prevalent mutations of CDKN2A/p16 associated
with the development of melanoma is the p16-Leiden mutation, represented by the deletion of 19 bp in exon 2 that leads to loss of the tumor-suppressive function of p16 INK4 (22). Approximately 70% of p16-Leiden mutation carriers are estimated to develop melanoma (23) and 15-20% of them are expected to develop PC (24-26).

The great clinical heterogeneity that characterizes FAMMM syndrome and the variations in associated cancers results not only
from the different types of CDKN2A mutations, but also from the influences of other genetic and environmental factors (27). Given the extremely aggressive behavior and poor prognosis of both melanoma and PC, the identification of individuals at risk for one or both of these cancers and their close surveillance is of utmost importance. Hence, further research has led to the detection of multiple genetic factors that modify the risk of melanoma and PC in p16-Leiden mutation carriers, such as melanocortin 1 receptor gene (MC1R) variants that influence the risk of melanoma (28,29), rs36115365-C, a single-nucleotide polymorphism which controls TERT expression and is associated with increased risk of PC and decreased risk of melanoma (30,31), mutations in glutathione S-transferase genes GSTM1 and GSTT1 (32), as well as in the vitamin D receptor gene that appear to have a slight protective effect against melanoma (33).

The benefits of regular skin checkup of FAMMM kindreds are indisputable. On the other hand, mortality from PC even exceeds mortality attributable to melanoma (34,35). Screening for PC is considerably more complicated. There is no universally accepted screening protocol for PC, but annual laboratory tests, such as the determination of the serum level of alkaline phosphatase, pancreatic enzymes and tumor markers (carcinoembryonic antigen and CA19.9) and imagistic investigations (abdominal ultrasound, computed tomography, or magnetic resonance imaging) are recommended in high-risk individuals (26,36,37).

In conclusion, clinicians should be aware of the strong association between FAMMM and PC. The reported case underlines the importance of regular skin checkups and screening for PC in patients with dysplastic nevus syndrome.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

LGP, CG, CN and MMM conceptualized and designed the study and the methodology. CG and MMM supervised the study. SN, TT and MMM participated in the acquisition, analysis and interpretation of data. CS, AMP, TT and CB researched the literature and drafted the manuscript. LGP, CG, CN, SN and MMM reviewed and edited the final manuscript. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Elias Emergency University Hospital, Bucharest, Romania (approval no. 4902). Written informed consent was provided by the patient.

Patient consent for publication

The patient provided written informed consent for the publication of the data.

Competing interests

The authors declare that they have no competing interests.

References

1. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T and Omlin A: Multiple primary tumours: Challenges and approaches, a review. ESMO Open 2: e000172, 2017.
2. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Weldon W, Ruhl J, Howlader N, Tatalovich Z, Cho H, et al (eds): SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, MD, 2010. Available from: http://seer.cancer.gov/csr/1975_2007.
3. Leone G, Pagano L, Ben-Yehuda D and Voso MT: Therapy-related leukemia and myelodysplasia: Susceptibility and incidence. Haematologica 92: 1380-1398, 2007.
4. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JYN, Wang JC and Liu LF: Roles of DNA topoisoomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci USA 104: 11014-11019, 2007.
5. Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, et al: Multi-institutional validation study of the American joint commission on cancer (8th edition) changes for T and N staging in patients with pancreatic adenocarcinoma. Ann Surg 265: 185-191, 2017.
6. Kang MJ, Jang JY, Chang YR, Kwon W, Jung W and Kim SW: Revisiting the concept of lymph node metastases of pancreatic head cancer: Number of metastatic lymph nodes and lymph node ratio according to N stage. Ann Surg Oncol 21: 1545-1551, 2014.
7. Ghiorzo P, Cotti P, Mantelli M, Houeaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, et al: Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 83: 441-448, 1999.
8. Bergman W, Watson P, de Jong J, Lynch HT and Fusaro RM: Systemic cancer and the FAMMM syndrome. Br J Cancer 61: 932-936, 1990.
9. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D IV and Organic SM: Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 100: 350S-355S, 1993.
10. Goldstein AM, Fraser MC, Struwing JP, Hassussian CJ, Ranade K, Zamerkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, et al: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333: 970-974, 1995.
11. Sewardow AJ, Storm HH and Sasiendi P: Risks of second primary malignancy in patients with cutaneous and ocular melanoma in Denmark, 1943-1989. Int J Cancer 61: 773-779, 1995.
12. Bergman W, Palan A and Went LN: Clinical and genetic studies in six Dutch kindreds with the dysplastic nevus syndrome. Ann Hum Genet 50: 249-258, 1986.
13. Gabree M, Patel D and Rodgers L: Clinical applications of melanoma genetics. Curr Treat Options Oncol 15: 336-350, 2014.
14. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, et al: High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66: 9818-9828, 2006.
15. Goldstein AM, Chan M, Harland M, Hayward NK, Demenas F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, et al: Features associated with germine CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet 44: 99-106, 2007.
16. Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, Neering H and Lynch JF: Tumour spectrum in the FAMMM syndrome. Br J Cancer 44: 553-560, 1981.
17. Fusaro RM, Lynch HT, Lynch JF and Madsen NJ: Phenotypic variation and systemic cancer in the FAMMM syndrome. Pigment Cell Res 1: 152-157, 1988.

18. Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P and Ghioldro P: Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev 36: 77-90, 2017.

19. Whelan AJ, Bartsch D and Goodfellow PJ: Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333: 975-977, 1995.

20. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32, 1994.

21. Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707, 1993.

22. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10: 351-353, 1995.

23. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, et al.: Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94: 894-903, 2002.

24. Vasen HF, Gruis NA, Frants RR, van Der Velden PA, Hille ET and Bergman W: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87: 809-811, 2000.

25. de Snoo FA, Bergman W, van Leeuwen I, van der Drift C, van Nieuwpoort FA, Out-Luiting CJ, Vasen HF, ter Huurne JA, Frants RR, et al.: Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14: 7151-7157, 2008.

26. Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthai E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, et al.: Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34: 2010-2019, 2016.

27. Bergman W and Gruis N: Familial melanoma and pancreatic cancer. N Engl J Med 334: 471-472, 1996.

28. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR and Gruis NA: Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69: 774-779, 2001.

29. Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, et al.: Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: A GenoMEL study. J Natl Cancer Inst 102: 1568-1583, 2010.

30. Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al.: Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nat Commun 8: 15034, 2017.

31. Rachakonda S, Kong H, Srinivas N, Garcia-Casado Z, Requena C, Fallah M, Heidenreich B, Planelles D, Traves V, Schadendorf D, et al.: Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk. Genes Chromosomes Cancer 57: 564-572, 2018.

32. Fortes C, Mastroeni S, Melchi F, Anzidei P, Innocenzi L, Giovannazzo R, Antonelli G, Pasquini P and Venanzetti F: P5 polymorphisms in GSTM1, GSTT1, coffee consumption and cutaneous melanoma risk. Melanoma Res 20: e45-e46, 2010.

33. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, et al.: Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur J Cancer 45: 3271-3281, 2009.

34. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin 70: 7-30, 2020.

35. Hille ET, van Duijn E, Hruban RH, Lightdale CJ, Lemon SJ, Lynch JF, Fusaro LR, Fusaro RM and Ghadriar P: Familial pancreatic cancer: A review. Semin Oncol 23: 251-275, 1996.

36. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC and Kimmey MB: Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131: 247-255, 1999.